BIOLOGY
纳安生物
T320-ADC
- Commodity name： T320-ADC
- Field of treatment and diagnosis： Cervical cancer, lung cancer, pancreatic cancer
- Dosing type： Intravenous injection
- Drug development stage： Clinical approval documents for preparation production
- 产品描述
-
T320 is a fully humanized antibody-coupled drug (ADC) with indications for a variety of malignant solid tumors, including pancreatic cancer, cervical cancer, ovarian cancer, lung cancer, etc., and belongs to a new class of national drugs.After T320 binds to the tumor surface antigen, it internalizes, releases cytotoxic molecules, and kills tumor cells.The clinical trial will target the terminal medication of patients with advanced tumors and will be divided into clinical phase I and clinical phase II.It has obtained domestic authorized patents in March 2024, completed all pharmaceutical and non-clinical toxicological safety evaluation studies in 2024, and declared clinical trial approvals in the United States, China, and Australia.
